As previously mentioned, CD99 is overexpressed on disease-initiating cells in most AML cases, especially in the more immature CD34+/CD38− cells often linked to chemoresistance and a reduced ability to trigger immune responses [97]. This evidence concerns the gene CD34 and acute myeloid leukemia.